ATE236261T1 - Dna-expressionssysteme basierend auf alphaviren - Google Patents

Dna-expressionssysteme basierend auf alphaviren

Info

Publication number
ATE236261T1
ATE236261T1 AT92900560T AT92900560T ATE236261T1 AT E236261 T1 ATE236261 T1 AT E236261T1 AT 92900560 T AT92900560 T AT 92900560T AT 92900560 T AT92900560 T AT 92900560T AT E236261 T1 ATE236261 T1 AT E236261T1
Authority
AT
Austria
Prior art keywords
alphaviruses
expression systems
systems based
dna expression
recombinant
Prior art date
Application number
AT92900560T
Other languages
English (en)
Inventor
Henrik Garoff
Peter Liljestroem
Original Assignee
Bioption Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20381182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE236261(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioption Ab filed Critical Bioption Ab
Application granted granted Critical
Publication of ATE236261T1 publication Critical patent/ATE236261T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT92900560T 1990-12-13 1991-12-12 Dna-expressionssysteme basierend auf alphaviren ATE236261T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003978A SE9003978D0 (sv) 1990-12-13 1990-12-13 Dna expressionssystem baserade paa ett virus replikon
PCT/SE1991/000855 WO1992010578A1 (en) 1990-12-13 1991-12-12 Dna expression systems based on alphaviruses

Publications (1)

Publication Number Publication Date
ATE236261T1 true ATE236261T1 (de) 2003-04-15

Family

ID=20381182

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900560T ATE236261T1 (de) 1990-12-13 1991-12-12 Dna-expressionssysteme basierend auf alphaviren

Country Status (12)

Country Link
US (3) US5739026A (de)
EP (1) EP0561890B1 (de)
JP (2) JP3435511B2 (de)
AT (1) ATE236261T1 (de)
AU (1) AU656545B2 (de)
CA (2) CA2614365A1 (de)
DE (1) DE69133228T2 (de)
DK (1) DK0561890T3 (de)
ES (1) ES2195998T3 (de)
FI (1) FI932678A7 (de)
SE (1) SE9003978D0 (de)
WO (1) WO1992010578A1 (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
EP0694070B1 (de) 1993-09-15 2002-04-10 Chiron Corporation Rekombinanter alphavirus vektor
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DE19512142A1 (de) * 1995-03-31 1996-10-02 Immuno Ag Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US5639650A (en) * 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6489167B1 (en) 1996-09-25 2002-12-03 The Government Of The United States As Represented By The Secretary Of The Department Of Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors
CA2268353A1 (en) * 1996-10-10 1998-04-16 Henrik Garoff Alphavirus-retrovirus vectors
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
DE69838483T2 (de) 1997-10-14 2008-07-03 Darwin Molecular Corp. Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
EP1029052B1 (de) 1997-11-06 2010-08-04 Novartis Vaccines and Diagnostics S.r.l. Neisseriale antigene
US20030180257A1 (en) 1997-11-14 2003-09-25 Mark Parrington Alphavirus vectors for paramyxovirus vaccines
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
AU754320B2 (en) 1998-04-08 2002-11-14 University Of North Carolina At Chapel Hill, The Methods and modified cells for the treatment of cancer
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
US6719980B1 (en) * 1998-05-08 2004-04-13 Akzo Nobel Nv Structural proteins of fish pancreatic disease virus and uses thereof
ATE386804T1 (de) 1998-10-15 2008-03-15 Novartis Vaccines & Diagnostic Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
CN1193791C (zh) * 1998-11-30 2005-03-23 希托斯生物技术股份公司 抗原的有序分子呈递,制备及使用的方法
JP2003524389A (ja) 1998-12-16 2003-08-19 カイロン コーポレイション ヒトサイクリン依存的キナーゼ（ｈＰＮＱＡＬＲＥ）
US8647864B2 (en) * 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2000061772A2 (en) * 1999-04-14 2000-10-19 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6297013B1 (en) 1999-06-24 2001-10-02 Dnab Diagnostics Inc. Compositions and methods for determining the activity of DNA-binding proteins and of initiation of transcription
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2003512829A (ja) 1999-10-22 2003-04-08 アヴェンティス パストゥール リミテッド 改変型ｇｐ１００およびその使用
WO2001031046A1 (en) * 1999-10-26 2001-05-03 International Aids Vaccine Initiative Invasive bacterial vectors for expressing alphavirus replicons
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
EP2163626A1 (de) 1999-11-18 2010-03-17 Novartis Vaccines and Diagnostics, Inc. Menschliches FGF-21 Gen und Genexpressionsprodukte
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
JP2003531583A (ja) 2000-03-08 2003-10-28 カイロン コーポレイション ヒトｆｇｆ−２３遺伝子および遺伝子発現産物
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CA2408328C (en) * 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
EP1349917B1 (de) 2000-12-08 2010-03-10 Life Technologies Corporation Verfahren und zusammensetzungen zur synthese von nukleinsäuremolekülen unter verwendung multipler erkennungsstellen
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) * 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP1383513B1 (de) * 2001-03-27 2010-10-20 New York University Tumortherapie mit vektoren auf sindbis virus-basis
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
EP2842964A1 (de) 2001-06-05 2015-03-04 Curevac GmbH Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
US7115266B2 (en) * 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
US7877273B2 (en) * 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
US20030219459A1 (en) * 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
US7615229B2 (en) 2002-03-15 2009-11-10 Wyeth Holdings Corporation Mutants of the P4 protein of nontypable Haemophilus influenzae with reduced enzymatic activity
EP1864691B1 (de) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modifizierte CEA-Nukleinsäure und entsprechende Expressionsvektoren
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
PL375306A1 (en) * 2002-06-20 2005-11-28 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP1524994B1 (de) 2002-07-19 2011-04-27 Cytos Biotechnology AG Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
AU2003284239B2 (en) 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
ES2630222T3 (es) 2002-12-13 2017-08-18 Alphavax, Inc. Partículas alfavíricas y métodos de preparación
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
AU2004204456A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
CN1791678A (zh) 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP1623229A2 (de) * 2003-05-15 2006-02-08 Cytos Biotechnology AG Selektion von b-zellen mit gewünschter spezifität: verfahren zur herstellung und deren verwendung
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
ATE506444T1 (de) * 2003-10-08 2011-05-15 Sanofi Pasteur Ltd Modifizierter cea/b7-vektor
KR20060128924A (ko) * 2004-01-20 2006-12-14 사이토스 바이오테크놀로지 아게 그레린-담체 접합체
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
AU2005245956B2 (en) 2004-05-18 2011-05-19 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
US20070248617A1 (en) * 2004-06-02 2007-10-25 Bachmann Martin F Medical Uses of Carrier Conjugates of Non-Human Tnf -Peptides
WO2005122675A2 (en) * 2004-06-21 2005-12-29 Quattromed As Optimized recognition site of the alphavirus non-structural protease for tag removal and specific processing of recombinant proetins
US7862829B2 (en) * 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
EP1856250B1 (de) * 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill Neue lebende virus-impfstoffe
EP3312196B1 (de) 2005-03-23 2019-07-17 Genmab A/S Antikörper gegen cd38 zur behandlung von multiplem myelom
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
EP2066346B1 (de) 2006-09-12 2019-07-03 AlphaVax, Inc. Für il-12 kodierende alphavirusreplikationspartikel als immunologische hilfsstoffe
WO2008033966A2 (en) 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
EP2139447A2 (de) 2007-03-20 2010-01-06 Harold Brem Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
NZ582495A (en) 2007-06-21 2012-05-25 Alphavax Inc Promoterless cassettes for expression of alphavirus structural proteins
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
WO2010065414A1 (en) 2008-12-01 2010-06-10 Alphavax, Inc. Use of micrornas to control virus helper nucleic acids
ES2540958T3 (es) 2009-04-08 2015-07-15 Alphavax, Inc. Partículas de replicón de alfavirus que expresan TRP2
WO2011038063A1 (en) 2009-09-28 2011-03-31 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
EE05711B1 (et) 2009-10-07 2014-04-15 Tartu Ülikool Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
WO2011064437A2 (es) 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US9198975B2 (en) 2010-12-01 2015-12-01 The University Of North Carolina At Chapel Hill Methods and compositions for targeting sites of neovascular growth
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US20190282679A1 (en) 2016-04-18 2019-09-19 Rima McLeod Toxoplasma gondii vaccines and their use
DK3585892T3 (da) * 2017-02-27 2022-08-22 Translate Bio Inc Fremgangsmåder til oprensning af messenger-rna
CN214973877U (zh) 2019-08-09 2021-12-03 胡桃钳医疗公司 用于形成治疗性多核苷酸的微流体设备及微流体路径装置
EP4648781A1 (de) 2023-01-12 2025-11-19 Bavarian Nordic A/S Rekombinante modifizierte sarna (vrp) für krebsimpfstoff

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1288073C (en) * 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US4943628A (en) * 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems

Also Published As

Publication number Publication date
DK0561890T3 (da) 2003-07-21
SE9003978D0 (sv) 1990-12-13
ES2195998T3 (es) 2003-12-16
CA2098292A1 (en) 1992-06-14
FI932678L (fi) 1993-07-27
JP2003159085A (ja) 2003-06-03
AU9078791A (en) 1992-07-08
DE69133228T2 (de) 2003-10-30
EP0561890A1 (de) 1993-09-29
JPH06504198A (ja) 1994-05-19
FI932678A7 (fi) 1993-07-27
EP0561890B1 (de) 2003-04-02
JP3435511B2 (ja) 2003-08-11
JP4018479B2 (ja) 2007-12-05
AU656545B2 (en) 1995-02-09
US20020151067A1 (en) 2002-10-17
US5739026A (en) 1998-04-14
WO1992010578A1 (en) 1992-06-25
US6190666B1 (en) 2001-02-20
CA2614365A1 (en) 1992-06-25
DE69133228D1 (de) 2003-05-08
FI932678A0 (fi) 1993-06-11

Similar Documents

Publication Publication Date Title
DE69133228D1 (de) Dna-expressionssysteme basierend auf alphaviren
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
DE69131580D1 (de) GDF-1 und UOG1 Proteine
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
DK0941318T5 (da) Håndvægtformede konstruerede ekspressionssystemer til genterapi
DK0757717T3 (da) Papillomavirusvacciner
MY102472A (en) Preparation of funtional human urokinase proteins.
DE3888086D1 (de) Rekombinantes Geflügelpockenvirus, Expressionsvektoren für heterologische Proteine und davon derivierte Geflügelvakzine.
DK251890A (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ATE381351T1 (de) Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten
NO950420D0 (no) Interferon endelse derav
BR0010222A (pt) Vetores de expressão viral
AR024989A1 (es) Medios de transformacion de hongos y uso de los mismos para la produccion de proteinas heterologas.
SE8100581L (sv) Gen och underenhet till densamma, plastmidvektor innehallande denna gen eller ungerenhet, forfarande for genens, underenhetens och vektorns framstellning och anvendning samt salunda erhallna celler och interferonlikn...
BR9915970A (pt) Vìrus recombinante expressando dna exógenocodificando cd80 felino, ctla-4 felino ou cd86 felinoe usos do mesmo
DE60026666D1 (de) Induktion von antigen-spezifischen T-Zellen durch Interferon
KR830010193A (ko) 바실러스 클로닝 매개체, 재결합 dna분자 그것들과 함께 변형된 간균 숙주 그리고 이종(異知) dna배열의 표현 방법과 그것으로 이루어진 폴리펩타이드의 생성방법
ATE102252T1 (de) Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine.
ATE93893T1 (de) Expressionssysteme zur ueberproduktion gewuenschter proteine.
BR9810046A (pt) Sequência de nucleotìdeos, vetor de expressão, célula hospedeira, proteìna de esperma de mamìfero, proteìna de esperma recombinante, proteìna 4, 1 e/ou 6,7 de esperma, composição farmacêutica, e, vacina contraceptiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0561890

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked